Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Biliary Tract Neoplasms × trastuzumab deruxtecan × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 62 Neoplasm Metastasis 23 Stomach Neoplasms 12 Carcinoma, Non-Small-Cell Lung 11 Colorectal Neoplasms 8 Brain Neoplasms 8 Neoplasms 7 Adenocarcinoma 6 Triple Negative Breast Neoplasms 5 Ovarian Neoplasms 4 Endometrial Neoplasms 4 Salivary Gland Neoplasms 3 Recurrence 3 Pancreatic Neoplasms 3 Esophageal Neoplasms 3 Advanced Solid Tumor 3 Sarcoma 2 Prostatic Neoplasms 2 Neoplasm, Residual 2 Meningeal Carcinomatosis 2 Melanoma 2 HER2-positive Gastric Cancer 2 HER2-positive Breast Cancer 2 Gastrointestinal Neoplasms 2 Carcinoma, Renal Cell 2 Breast Cancer With Brain Metastasis 2 Advanced Breast Cancer 2 Vulvar Neoplasms 1 Vaginal Neoplasms 1 Uterine Neoplasms 1

Interventions

Gemcitabine 82 Cisplatin 65 Capecitabine 34 Oxaliplatin 31 durvalumab 29 pembrolizumab 24 Fluorouracil 23 Leucovorin 22 S 1 (combination) 16 lenvatinib 12 Nivolumab 12 Irinotecan 12 tremelimumab 10 Bevacizumab 10 130-nm albumin-bound paclitaxel 9 Injections 7 Immune Checkpoint Inhibitors 7 Docetaxel 7 apatinib 6 Trastuzumab 6 titanium silicide 5 surufatinib 5 irinotecan sucrosofate 5 camrelizumab 5 Folfox protocol 5 Drug Therapy 5 Carboplatin 5 Blood Specimen Collection 5 Albumin-Bound Paclitaxel 5 zanidatamab 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06467357 2026-02-17

DESTINY-BTC01

AstraZeneca

Phase 3 Recruiting

Gastrointestinal

Biliary Tract Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡